Intellectual Property India Publishes Patent Application for 'Bispecific Antibody, Drug Conjugate Thereof, And Use Thereof' Filed by Duality Biologics (SUZHOU) Co. Ltd.

MUMBAI, India, March 14 -- Intellectual Property India has published a patent application (202617017213 A) filed by Duality Biologics (SUZHOU) Co. Ltd., Jiangsu, China, on Feb. 16, for 'bispecific antibody, drug conjugate thereof, and use thereof.'

Inventor(s) include Zhou, Yunhua; Hua, Haiqing; Yang, Junjie; and Zhu, Zhongyuan.

The application for the patent was published on March 13, under issue no. 11/2026.

According to the abstract released by the Intellectual Property India: "Provided are a bispecific antibody, a drug conjugate thereof, and a use thereof. The bispecific antibody comprises an EGFR binding domain and an HER3 binding domain. The provided bispecific antibody and the drug conjugate thereof have excellent endocytosis effects, proliferation inhibition activity and tumor growth inhibition activity, as well as good in vivo safety."

The patent application was internationally filed on July 19, 2024, under International application No.PCT/CN2024/106435.

Disclaimer: Curated by HT Syndication.